Table 2.
Clinical and treatment baseline characteristics of the patients in both groups during breast nurse intervention.
| Characteristics | Intervention group | Control group |
|---|---|---|
| Frequency (%) | Frequency (%) | |
| Total visits to hospital till diagnosis | ||
| 1-2 | 40 (46.0) | 31 (41.9) |
| 3-5 | 38 (43.7) | 38 (51.4) |
| ≥6 | 9 (10.3) | 5 (6.8) |
| Mean (SD) | 3.02 (1.64) | 3.08 (1.82) |
| Advised to go to other places (for diagnosis or treatment) |
||
| Yes | 39 (44.8) | 65 (86.7) |
| No | 48 (55.2) | 10 (13.3) |
| Stage at presentation | ||
| I | 6 (6.9) | 5 (6.7) |
| II | 41 (47.1) | 17 (22.7) |
| III | 36 (41.4) | 49 (65.3) |
| IV | 4 (4.6) | 4 (5.3) |
| FNAC conducted | ||
| Yes | 59 (67.8) | 71 (94.7) |
| No | 28 (32.2) | 4 (5.3) |
| Histology result | ||
| Ductal carcinoma | 84 (96.6) | 68 (90.7) |
| Lobular carcinoma | 3 (3.4) | 7 (9.3) |
| Days interval from diagnosis to surgery in days |
||
| <30 | 51 (58.6) | 41 (54.7) |
| 31-60 | 11 (12.6) | 3 (4.0) |
| 61-90 | 4 (4.6) | 5 (6.7) |
| ≥91 | 21 (24.1) | 26 (34.7) |
| Median (IQR) | 18 (3, 80) | 22 (5, 115) |
| History of using chemotherapy before |
||
| Yes | 18 (20.7) | 13 (17.3) |
| No | 69 (79.3) | 62 (82.7) |
| History of using radiotherapy | ||
| Yes | 6 (6.9) | 6 (8.0) |
| No | 81 (93.1) | 69 (92.0) |
| History of using tamoxifen | ||
| Yes | 16 (18.4) | 4 (5.3) |
| No | ||
| ER/PR status | 71 (81.6) | 71 (94.7) |
| Positive | 10 (11.5) | 16 (21.3) |
| Unknown | 77 (88.5) | 59 (78.7) |
| HER2 status | ||
| HER2+ | 4 (4.6) | 3 (4.0) |
| HER2– | 6 (6.9) | 13 (17.3) |
| Unknown | 77 (88.5) | 59 (78.7) |
| Had comorbidity illness | ||
| Yes | 14 (16.1) | 8 (10.7) |
| No | 73 (83.9) | 67 (89.3) |
| Type of comorbid illness | ||
| Stroke | 3 (21.4) | 2 (25.0) |
| Hypertension | 8 (57.1) | 3 (37.5) |
| Heart disease | 1 (7.1) | 2 (25.5) |
| Others | 2 (14.3) | 1 (12.5) |
FNAC, fine needle aspiration cytology; ET, endocrine therapy; ER/PR, estrogen progesterone receptor; HER2, human epidermal receptor 2.